A vs AMAT Stock Comparison

Scores Breakdown

Metric	A	AMAT
📈 Growth	18/30	28/30
💰 Profitability	16/20	18/20
🏦 Financial Health	7/20	16/20
💵 Valuation	9/20	14/20
⚠️ Risk (lower is better)	7/10	6/10
Overall Score	53/100	80/100

Side-by-Side Summaries

A Analysis	AMAT Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles. 💰 Margins & Cash Flow Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026. Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range). Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation. 🛡️ Balance Sheet & Liquidity Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods. ⚠️ Key Drivers & Risks Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries. Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

A Analysis

AMAT Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles.

💰 Margins & Cash Flow

Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026.
Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range).
Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation.

🛡️ Balance Sheet & Liquidity

Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries.
Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"